259 related articles for article (PubMed ID: 12496151)
1. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.
Ren B; Szalai AJ; Thomas O; Hollingshead SK; Briles DE
Infect Immun; 2003 Jan; 71(1):75-85. PubMed ID: 12496151
[TBL] [Abstract][Full Text] [Related]
2. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.
Ren B; Szalai AJ; Hollingshead SK; Briles DE
Infect Immun; 2004 Jan; 72(1):114-22. PubMed ID: 14688088
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.
Ochs MM; Bartlett W; Briles DE; Hicks B; Jurkuvenas A; Lau P; Ren B; Millar A
Microb Pathog; 2008 Mar; 44(3):204-14. PubMed ID: 18006268
[TBL] [Abstract][Full Text] [Related]
4. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection.
Ren B; McCrory MA; Pass C; Bullard DC; Ballantyne CM; Xu Y; Briles DE; Szalai AJ
J Immunol; 2004 Dec; 173(12):7506-12. PubMed ID: 15585877
[TBL] [Abstract][Full Text] [Related]
5. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.
Tu AH; Fulgham RL; McCrory MA; Briles DE; Szalai AJ
Infect Immun; 1999 Sep; 67(9):4720-4. PubMed ID: 10456922
[TBL] [Abstract][Full Text] [Related]
6. The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro.
Ren B; Li J; Genschmer K; Hollingshead SK; Briles DE
Clin Vaccine Immunol; 2012 Oct; 19(10):1574-82. PubMed ID: 22855389
[TBL] [Abstract][Full Text] [Related]
7. Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice.
Quin LR; Moore QC; McDaniel LS
Infect Immun; 2007 Apr; 75(4):2067-70. PubMed ID: 17220305
[TBL] [Abstract][Full Text] [Related]
8. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae.
Roche H; Ren B; McDaniel LS; Håkansson A; Briles DE
Infect Immun; 2003 Aug; 71(8):4498-505. PubMed ID: 12874329
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.
Mukerji R; Mirza S; Roche AM; Widener RW; Croney CM; Rhee DK; Weiser JN; Szalai AJ; Briles DE
J Immunol; 2012 Dec; 189(11):5327-35. PubMed ID: 23105137
[TBL] [Abstract][Full Text] [Related]
10. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.
Abeyta M; Hardy GG; Yother J
Infect Immun; 2003 Jan; 71(1):218-25. PubMed ID: 12496169
[TBL] [Abstract][Full Text] [Related]
11. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae.
Briles DE; Yother J; McDaniel LS
Rev Infect Dis; 1988; 10 Suppl 2():S372-4. PubMed ID: 3187321
[TBL] [Abstract][Full Text] [Related]
12. Streptococcus pneumoniae Binds to Host Lactate Dehydrogenase via PspA and PspC To Enhance Virulence.
Park SS; Gonzalez-Juarbe N; Martínez E; Hale JY; Lin YH; Huffines JT; Kruckow KL; Briles DE; Orihuela CJ
mBio; 2021 May; 12(3):. PubMed ID: 33947761
[TBL] [Abstract][Full Text] [Related]
13. Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model.
Ogunniyi AD; LeMessurier KS; Graham RM; Watt JM; Briles DE; Stroeher UH; Paton JC
Infect Immun; 2007 Apr; 75(4):1843-51. PubMed ID: 17261599
[TBL] [Abstract][Full Text] [Related]
14. Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae septicemia.
Yuste J; Botto M; Paton JC; Holden DW; Brown JS
J Immunol; 2005 Aug; 175(3):1813-9. PubMed ID: 16034123
[TBL] [Abstract][Full Text] [Related]
15. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae.
Daniels CC; Briles TC; Mirza S; Håkansson AP; Briles DE
Microb Pathog; 2006 May; 40(5):228-33. PubMed ID: 16540281
[TBL] [Abstract][Full Text] [Related]
16. Characterization of binding of human lactoferrin to pneumococcal surface protein A.
Håkansson A; Roche H; Mirza S; McDaniel LS; Brooks-Walter A; Briles DE
Infect Immun; 2001 May; 69(5):3372-81. PubMed ID: 11292760
[TBL] [Abstract][Full Text] [Related]
17. The genetic background of Streptococcus pneumoniae affects protection in mice immunized with PspA.
He X; McDaniel LS
FEMS Microbiol Lett; 2007 Apr; 269(2):189-95. PubMed ID: 17355599
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media.
Schachern PA; Tsuprun V; Ferrieri P; Briles DE; Goetz S; Cureoglu S; Paparella MM; Juhn S
Int J Pediatr Otorhinolaryngol; 2014 Sep; 78(9):1517-21. PubMed ID: 25015773
[TBL] [Abstract][Full Text] [Related]
19. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).
McDaniel LS; Yother J; Vijayakumar M; McGarry L; Guild WR; Briles DE
J Exp Med; 1987 Feb; 165(2):381-94. PubMed ID: 3546575
[TBL] [Abstract][Full Text] [Related]
20. PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation.
Li J; Glover DT; Szalai AJ; Hollingshead SK; Briles DE
Infect Immun; 2007 Dec; 75(12):5877-85. PubMed ID: 17923519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
